ADVANCES IN NONINVASIVE DRUG DELIVERY SYSTEMS OF OPIOIDS: FORMULATIONS AND CLINICAL PERSPECTIVE
Abstract
ABSTRACT
Opioid continues as the main pharmacological treatment for severe acute pain. Extensive first-pass metabolism is the major limitation of opioid
delivery by oral route. Thus, the parenteral route has been the only option for the delivery of opioids before the beginning of the 21
century.
However, as the delivery through parenteral route is associated with limitation of being invasive, a strong need for developing non-invasive delivery
systems has been felt among the drug delivery scientists. Since mucosal surfaces are rich in blood supply and provide rapid drug transport to the
systemic circulation, this delivery system has been explored to enhance opioid bioavailability by avoiding their degradation through first-pass hepatic
metabolism. Oral transmucosal delivery such as buccal and sublingual has progressed far beyond the use of traditional dosage forms developed with
novel approaches emerging continuously. This review provides updated information about the use of opioids for the treatment of severe pain with
special emphasis on the work done by various scientists on formulation development of opioid analgesics, especially by buccal and sublingual route
for delivery of opioids along with their clinical perspective. Particular attention is given to new approaches enhancing bioavailability of opioids by
these routes.
Keywords: Opioids, Buccal, Oral drug, Sublingual delivery of opioids.
st
Downloads
References
REFERENCES
Nersesyan H, Slavin KV. Current approach to cancer pain management:
Availability and implications of different treatment options. Ther Clin
Risk Manag 2007;3(3):381-400.
Rang HP, Dale MM, Ritter JM. Rang & Dale’s Pharmacology. 6
ed.
Edinburg: Churchill Livingstone; 2007.
Stevens RA, Ghazi SM. Routes of opioid analgesic therapy in the
management of cancer pain. Cancer Control 2000;7(2):132-41.
Morales ME, Gallardo Lara V, Calpena AC, Doménech J, Ruiz MA.
Comparative study of morphine diffusion from sustained release
polymeric suspensions. J Control Release 2004;95(1):75-81.
Koocheki S, Madaeni SS, Niroomandi P. Development of an enhanced
formulation for delivering sustained release of buprenorphine
hydrochloride. Saudi Pharm J 2011;19(4):255-62.
Zamloot M, Chao W, Kang LL, Ross J, Fu R. Remoxy
: A novel
formulation of extended release oxycodone developed using the
Oradur
technology. J Appl Res 2010;10(3):88-96.
Friedmann N, Klutzaritz V, Webster L. Long-term safety of Remoxy®
®
(extended-release oxycodone) in patients with moderate to severe
chronic osteoarthritis or low back pain. Pain Med 2011;12(5):755-60.
Senel S, Kremer M, Nagy K, Squier C. Delivery of bioactive peptides
and proteins across oral (buccal) mucosa. Curr Pharm Biotechnol
;2(2):175-86.
®
th
Asian J Pharm Clin Res, Vol 9, Issue 4, 2016, 341-347
Mundhey et al.
Lalla JK, Gurnacy RA. Polymers for mucosal delivery swelling and
mucoadhesive evaluation. Indian Drugs 2002;39(5):270-6.
Sattar M, Sayed OM, Lane ME. Oral transmucosal drug delivery –
Current status and future prospects. Int J Pharm 2014;471(1-2):498-506.
Anlar S, Capan Y, Güven O, Gögüs A, Dalkara T, Hincal AA.
Formulation and in vitro-in vivo evaluation of buccoadhesive morphine
sulfate tablets. Pharm Res 1994;11(2):231-6.
Aiache JM. Process for preparing a bioadhesive pharmaceutical dosage
form and pharmaceutical dosage form thus prepared. U.S. Patent
,362,498 November 8, 1994.
Beyssac E, Touaref F, Meyer M, Jacob L, Sandouk P, Aiache JM.
Bioavailability of morphine after administration of a new bioadhesive
buccal tablet. Biopharm Drug Dispos 1998;19(6):401-5.
Gordon DB. New opioid formulations and delivery systems. Am Soc
Pain Manag Nurs 2007;8(3):S6-13.
Kim KS, Simon L. Transport mechanisms in oral transmucosal
drug delivery: Implications for pain management. Math Biosci
;229(1):93-100.
Rathbone M, Senel S, Pather I. Oral Mucosal Drug Delivery and
Therapy. 1
ed. New York, Heidelberg, London: Springer; 2015.
Comerford D. Techniques of opioid administration. Anaesth Intensive
st
Care Med 2008;9(1):21-6.
Schechter NL, Weisman SJ, Rosenblum M, Bernstein B, Conard PL.
The use of oral transmucosal fentanyl citrate for painful procedures in
children. Pediatrics 1995;95(3):335-9.
Highlights of Prescribing Information. FENTORA
Fentanyl Citrate
Buccal Tablet. Available from: http://www.accessdata.fda.gov/
drugsatfda_docs/label/2011/021947s013lbl.pdf.
®
Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG.
Pharmacokinetic properties of fentanyl effervescent buccal tablets: A
phase I, open-label, crossover study of single-dose 100, 200, 400, and
microg in healthy adult volunteers. Clin Ther 2006;28(5):707-14.
Manco L, Messina J, Portenoy R. A randomized, placebo controlled
study of fentanyl effervescent buccal tablets for breakthrough pain in
opioid tolerant patients with cancer. Poster Presented at 22
Annual
Meeting of American Academy of Pain Medicine 2006; Manchester, San
Diego. Available from: https://www.aapm.confex.com/aapm/2006am/
techprogram/P1161.HTM.
Kosugi T, Hamada S, Takigawa C, Shinozaki K, Kunikane H, Goto F,
et al. A randomized, double-blind, placebo-controlled study of fentanyl
buccal tablets for breakthrough pain: Efficacy and safety in Japanese
cancer patients. J Pain Symptom Manage 2014;47(6):990-1000.
Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the
relief of breakthrough pain in opioid tolerant adult patients with chronic
neuropathic pain: A multicentre, randomized, double blind, placebo
controlled study. Clin Ther 2007;29(4):588-601.
Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral
fentanyl formulations vs. oral morphine for cancer-related breakthrough
pain: A meta-analysis of comparative trials. J Pain Symptom Manage
;46(4):573-80.
Fine PG, Messina J, Xie F, Rathmell J. Long-term safety and tolerability
of fentanyl buccal tablet for the treatment of breakthrough pain in
opioid-tolerant patients with chronic pain: An 18-month study. J Pain
Symptom Manage 2010;40(5):747-60.
Hearnden V, Sankar V, Hull K, Juras DV, Greenberg M, Kerr AR, et al.
New developments and opportunities in oral mucosal drug delivery for
local and systemic disease. Adv Drug Deliv Rev 2012;64(1):16-28.
Tapolsky GH, Osborne DW. Bioerodable film for delivery of
pharmaceutical compounds of mucosal surface. U.S. Patent
,159,498 December 12, 2000.
Tapolsky GH, Osborne DW. Pharmaceutical carrier device suitable for
delivery of pharmaceutical compounds to mucosal surface. U.S. Patent
,579,019 August 25, 2009.
Gordon DB. Oral transmucosal fentanyl citrate for cancer breakthrough
pain: A review. Oncol Nurs Forum 2006;33(2):257-64.
Diaz del Consuelo I, Falson F, Guy RH, Jacques Y. Ex vivo evaluation
of bioadhesive films for buccal delivery of fentanyl. J Control Release
;122(2):135-40.
Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal
soluble film (FBSF) for breakthrough pain in patients with cancer:
A randomized, double-blind, placebo-controlled study. Ann Oncol
;21(6):1308-14.
Finn A, Vasisht N. Transmucosal delivery devices with enhanced
uptake. U.S. Patent 8,147,866 April 3, 2012.
Abuse-resistant mucoadhesive devices for delivery of buprenorphine.
U.S. Patent 8,703,177 April 22, 2014.
Bai SA, Xiang Q, Finn A. Evaluation of the pharmacokinetics of
nd
single - And multiple-dose buprenorphine buccal film in healthy
volunteers. Clin Ther 2016;38(28):358-69.
Sullivan JG, Webster L. Novel buccal film formulation of buprenorphinenaloxone
for
the maintenance treatment
of
opioid dependence:
A
-Week
conversion study.
Clin Ther
;37(5):1064-75.
Guo JH. Bioadhesive polymer buccal patches for buprenorphine
controlled delivery: Formulation, In vitro adhesion and release
properties. Drug Dev Ind Pharm 1994;20(18):2809-21.
Han RY, Fang JY, Sung KC, Hu OY. Mucoadhesive buccal disks for
novel nalbuphine prodrug controlled delivery: Effect of formulation
variables on drug release and mucoadhesive performance. Int J Pharm
;177(2):201-9.
Parodi B, Russo E, Caviglioli G, Vallarino M, Fusco F, Henriquet F.
Buccoadhesive oxycodone hydrochloride disks: Plasma
pharmacokinetics in healthy volunteers and clinical study. Eur J Pharm
Biopharm 1997;44(2):137-42.
Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug
delivery. J Control Release 2011;153(2):106-16.
Ciach T, Moscicka-Studzinska A. Buccal iontophoresis: An opportunity
for drug delivery and metabolite monitoring. Drug Discov Today
;16(7-8):361-6.
Streisand JB, Stanley TH. Newer drug delivery systems. Curr Anaesth
Crit Care 1995;6(2):113-20.
Campisi G, Giannola LI, Florena AM, De Caro V, Schumacher A,
Göttsche T, et al. Bioavailability in vivo of naltrexone following
transbuccal administration by an electronically-controlled intraoral
device: A trial on pigs. J Control Release 2010;145(3):214-20.
Giannola LI, De Caro V, Giandalia G, Siragusa MG, Tripodo C,
Florena AM, et al. Release of naltrexone on buccal mucosa: Permeation
studies, histological aspects and matrix system design. Eur J Pharm
Biopharm 2007;67(2):425-33.
Walton RP. Absorption of drugs through the oral mucosa: III. Fatwater
solubility coefficient
of
alkaloids.
Proc Soc Exp Bio Med
;32(9):1488-92.
Weinberg DS, Inturrisi CE, Reidenberg B, Moulin DE, Nip TJ,
Wallenstein S, et al. Sublingual absorption of selected opioid analgesics.
Clin Pharmacol Ther 1988;44(3):335-42.
Fudala PJ, Johnson RE. Development of opioid formulations
with limited diversion and abuse potential. Drug Alcohol Depend
;83 Suppl 1:S40-7.
Orange Book: Approved Drug Products with Therapeutic Equivalence
Evaluations. U.S. Food & Drug Administration.
Lewis JW, Lloyd JG. Analysis compositions. U.S. Patent 4,582,835 April
, 1986.
Pettersson A, Nystrom C. Pharmaceutical composition for the treatment
of acute disorder. U.S. Patent 8,454,996 B2 June 4, 2013.
Pettersson A. Non-abusable pharmaceutical composition comprising
opioids. U.S. Patent 8,470,361 B2 June 25, 2013.
Pettersson A. Non-abusable pharmaceutical composition comprising
opioids. U.S. Patent 8,658,198 B2 February 25, 2014.
Fischer A. Abuse resistant pharmaceutical composition for the treatment
of opioid dependence. U.S. Patent 8,940,330 B2 January 27, 2015.
Fischer A. Abuse resistant pharmaceutical composition for the treatment
of opioid dependence. U.S. Patent 9,259,421 B2 February 16, 2016.
Fischer A, Jönsson M, Hjelmström P. Pharmaceutical and
pharmacokinetic characterization of a novel sublingual buprenorphine/
naloxone tablet formulation in healthy volunteers. Drug Dev Ind Pharm
;41(1):79-84.
Bredenberg S, Duberg M, Lennernäs B, Lennernäs H, Pettersson A,
Westerberg M, et al. In vitro and in vivo evaluation of a new sublingual
tablet system for rapid oromucosal absorption using fentanyl citrate as
the active substance. Eur J Pharm Sci 2003;20(3):327-34.
Myers GL, Fuisz JM. Sublingual and buccal film compositions. U.S.
Patent 8,475,832 July 2, 2013.
Yang RK, Fuisz RC, Myers GL, Fuisz JM. Polyethylene oxidebased
films
and drug
delivery systems
made therefrom.
U.S.
Patent
,017,150
September
, 2011.
Yang RK, Fuisz RC, Myers GL, Fuisz JM. Uniform films for rapid
dissolve dosage form incorporating taste-masking compositions. U.S.
Patent 8,603,514 December 10, 2013.
Yeola GS, Darandale S, Khire A, Vavia PR. Fabrication and statistical
optimization of a polysaccharide-based sublingual film of buprenorphine
hydrochloride for breakthrough pain management: In vitro and in vivo
performance. Drug Deliv Transl Res 2014;4(2):116-25.
Soyka M. Buprenorphine-naloxone buccal soluble film for the
treatment of opioid dependence: Current update. Expert Opin Drug
Deliv 2015;12(2):339-47.
Asian J Pharm Clin Res, Vol 9, Issue 4, 2016, 341-347
Mundhey et al.
Ling W, Mooney L, Zhao M, Nielsen S, Torrington M, Miotto K.
Selective review and commentary on emerging pharmacotherapies for
opioid addiction. Subst Abuse Rehabil 2011;2:181-8.
Lintzeris N, Leung SY, Dunlop AJ, Larance B, White N, Rivas GR,
et al. A randomised controlled trial of sublingual buprenorphinenaloxone
film
versus
tablets in
the management
of
opioid dependence.
Drug
Alcohol
Depend 2013;131(1-2):119-26.
Lavonas EJ, Banner W, Bradt P, Bucher-Bartelson B, Brown KR,
Rajan P, et al. Root causes, clinical effects, and outcomes of
unintentional exposures to buprenorphine by young children. J Pediatr
;163(5):1377-83.e1-3.
Boyer EW, McCance-Katz EF, Marcus S. Methadone and buprenorphine
toxicity in children. Am J Addict 2010;19(1):89-95.
Buprenorphine prescribing practices and exposures reported to a
poison center – Utah, 2002-2011. MMWR Morb Mortal Wkly Rep
;61:997-1001.
Kottayil SG, Goskonda VR, Zhu Z, Parikh N, Kattookaran L. Sublingual
Fentanyl Spray. U.S. Patent 8,486,972 B2 July 16, 2013.
Kottayil SG, Goskonda VR, Zhu Z, Parikh N, Kattookaran L. Sublingual
fentanyl spray. U.S. Patent 8,486,973 B2 July 16, 2013.
Kottayil SG, Goskonda VR, Zhu Z, Parikh N, Kattookaran L. Sublingual
fentanyl spray. U.S. Patent 8,835,459 B2 September 16, 2014.
Parikh N, Goskonda V, Chavan A, Dillaha L. Single-dose
pharmacokinetics of fentanyl sublingual spray and oral transmucosal
fentanyl citrate in healthy volunteers: A randomized crossover study.
Clin Ther 2013;35(3):236-43.
Palmer PP, Royal MA, Miller RD. Novel delivery systems
for postoperative analgesia. Best Pract Res Clin Anaesthesiol
;28(1):81-90.
Griffin DW, Skowronski RJ, Dasu BN, Palmer PP. A phase 2 openlabel
functionality,
safety,
and efficacy
study of the sufentanil
NanoTab
PCA system in patients following elective unilateral
knee replacement surgery. In: Poster Presented at the 35
TM
Annual
Spring Meeting and Workshops of the American Society of Regional
Anesthesia and Pain Medicine; April 22-25. Toronto, Ontario,
Canada; 2010.
Minkowitz HS, Singla NK, Evashenk MA, Hwang SS, Chiang YK,
Hamel LG, et al. Pharmacokinetics of sublingual sufentanil tablets
and efficacy and safety in the management of postoperative pain. Reg
Anesth Pain Med 2013;38(2):131-9.
RxList The Internet Drug Index. Available from: http://www.rxlist.
com/script/main/hp.asp.
U.S. National Library of Medicine. Available from: http://www.
Dailymed.nlm.nih.gov/dailymed/index.cfm.
RxList The Internet Drug Index. DILAUDID
(hydromorphone
hydrochloride) 8 mg Tablets. Available from: http://www.rxlist.com/
dilaudid-drug/clinical-pharmacology.htm.
®
U.S. National Library of Medicine. Dailymed. OXYCONTIN –
Oxycodone Hydrochloride Tablet, Film Coated, Extended. Available
from: http://www.dailymed.nlm.nih.gov/dailymed/drugInfo.
cfm?setid= bfdfe235-d717-4855-a3c8-a13d26dadede.
U.S. National Library of Medicine. Dailymed. Oxycodone
Hydrochloride – OXYCODONE Hydrochloride Capsule. Available
from: http://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
th
setid=566ef 74d-5c0b-49bf-9619-e757d16431ef.
Pather IS, Khankari RK, Eichman JD, Robinson JR, Hontz J. Sublingual
buccal effervescent. U.S. Patent 6,200,604 March 13, 2001.
U.S. National Library of Medicine. Dailymed. FENTORA –
Fentanyl Citrate Tablet. Available from: http://www.dailymed.nlm.
nih.gov/dailymed/drugInfo.cfm?setid=8f549d95-985b-f783-1ebbef57bd2ecb05.
U.S. National Library of Medicine. Dailymed. LAZANDA –
Fentanyl Citrate Spray. Available from: http://www.dailymed.nlm.
nih.gov/dailymed/drugInfo.cfm?setid=9dcaff31-1653-11e3-8ffd0800200c9a66.
Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation
and Mitigation Strategy (REMS) ACCESS. Onsolis - Fentanyl buccal
soluble film. Available from: https://www.tirfremsaccess.com/TirfUI/
rems/pdf/onsolis-prescribing-information.pdf.
U.S. National Library of Medicine. Dailymed. DURAGESIC – Fentanyl
Patch. Available from: http://www.dailymed.nlm.nih.gov/dailymed/
drugInfo.cfm?setid=d7aade83-9e69-4cd5-8dab-dbf1d7b89bb4.
Pettersson A, et al. Fentanyl composition for the treatment of acute
pain. U.S. Patent 6,759,059 July 6, 2004.
U.S. National Library of Medicine. Dailymed. ABSTRAL –
Fentanyl Citrate Tablet. Available from: http://www.dailymed.nlm.
nih.gov/dailymed/drugInfo.cfm?setid=f969e2bc-6297-4e29-89d3a3685a2c7c6b.
George Kottayil S, Long Grove IL. Sublingual Fentanyl Spray. U.S.
Patent 8,486,972 July 16, 2013.
George Kottayil S, Long Grove IL. Sublingual fentanyl spray. U.S.
Patent 8,486,973 July 16, 2013.
George Kottayil S, Long Grove IL. Sublingual fentanyl spray. U.S.
Patent 8,835,459 September 16, 2014.
George Kottayil S, Long Grove IL Sublingual fentanyl spray and
methods of treating pain. U.S. Patent 8,835,460 September 16, 2014.
U.S. National Library of Medicine. Dailymed. SUBSYS – Fentanyl
Spray. Available from: http://www.dailymed.nlm.nih.gov/dailymed/
drugInfo.cfm?setid=18a413e9-11e0-4a8f-86c0-d33b37b7b771.
U.S. National Librar$y of Medicine. Dailymed. BUPRENORPHINE
HCL – Buprenorphine Hydrochloride Tablet. Available from: http://
www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm ?setid=1bf8b35ab769-465c-a2f8-099868dfcd2f.
U.S. National Library of medicine. Dailymed. BUNAVAIL –
Buprenorphine hydrochloride and naloxone hydrochloride dehydrate
film. Available from: http://www.dailymed.nlm.nih.gov/dailymed/
drugInfo.cfm?setid=12b963dd-f189-11e3-ac10-0800200c9a66.
U.S. National Library of Medicine. Dailymed. Butorphanol
Tartarate – Butorphanol Tartarate Spray. Available from: https://www.
dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c069ce5-ea674f42-afe4-30b01b4ce24d.
Meperidine HCl Tablet Demerol. Prescribing Information. SanofiAventis
Canada Inc. Available
from:
http://www.products.sanofi.ca/en/
demerol.pdf.
US. National Library of Medicine. Dailymed. Avinza - Morphine
Sulphate Capsule, Extended Release. Available from: https://www.
dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d06642a8-a26a4007-9ed6-812c4b87f1e8.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.